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Abstract. Tumour metastasis occurs as a result of a cascade of events including
alterations in the expression of various genes. The identification of such genes is
essential to understanding formation of metastasis. In a previous study, highly meta-
static (LN4.D6) and poorly metastatic (CAb.D5) cell lines were obtained from the rat
mammary adenocarcinoma cell line R3230AC. Subtractive hybridization was used to
identify differentially expressed genes between these two cell lines. We identified eight
cDNA clones in CAb.D5 and six cDNA clones in LN4.D6 that were differentially
expressed. One of the cDNA clones in each cell line had no homology with known
sequences. Expression patterns of these differentially expressed genes were examined
in a pair of rat mammary and prostate adenocarcinoma cell lines. Compared with cell
lines examined, cDNA FF-10 was only expressed in CAb.D5; however, cDNA RB-8,
RE-1, RF-5 were only expressed in the highly metastatic LN4.D6. No correlation was
observed between expression patterns of the differentially expressed genes and meta-
static potential of these cells. However, differential expression of genes, especially
cytokeratins (CK8 and CK5) and collagens (III and IV) between highly metastatic and
low metastatic rat mammary adenocarcinoma cell lines might initiate further investiga-
tion of these genes in metastatic process.
INTRODUCTION
Steps in human cancer progression have been well identified clinically. In some cases, pre-
malignant lesions exist in organs before they progress to malignant invasive tumours. These may
occur as a result of either genetic alterations or environmental factors. Accumulation of
mutations in a cell may convert it into a malignant phenotype which could give rise to a primary
tumour. At early stages of primary tumour growth, cells are not invasive nor metastatic. How-
ever, further accumulation of genetic alterations results in invasive and metastatic cells being
generated (reviewed by Yokota 2000). Metastasis is a multistep process in which tumour cells
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leave their primary location, invade surrounding normal tissue, penetrate into blood and
lymphatic vessels, escape host anti-tumour responses and establish secondary cancers in other
tissues (Liotta et al. 1991). The genetic events controlling this process are not yet well known.
Even though there has been significant improvement in diagnosis, most deaths from cancer are
still due to metastatic tumours. Therefore, identification of genes and gene products involved in
metastasis is the subject of many current studies.
A variety of experimental models is available for the investigation of cancer metastasis.
There is substantial evidence that tumours contain phenotypically and biologically heter-
ogeneous cell populations resulting from differences in the genes altered in each cancer cell
(Fidler et al. 1987). Based on this, a tumour subpopulation from R3230AC rat mammary
adenocarcinoma was selected in this laboratory which exhibited enhanced metastatic ability
to draining lymph nodes [and measured by lung colony formation after tail vein injection
(Carlsen et al. 1993)]; it was designated LN4 (Buckly & Carlsen 1988). This cell line was
shown to bind the lectin soybean agglutinin via neutral isoglobotetraosylceramide (iGb4Cer)
expressed on the cell surface (Buckly & Carlsen 1988; Carlsen et al. 1990; Carlsen et al. 1993).
When the LN4 cell subpopulation was depleted of cells expressing iGb4Cer by incubation
with an anti-iGb4Cer monoclonal antibody (mAb), the resulting cell line CAb exhibited
low metastatic activity (Carlsen et al. 1990). Recent studies have shown that expression of
iGb4Cer in highly metastatic cells results from a significant decrease in CMP-NeuAc :
lactosylceramideα2,3-sialyltransferase (GM3 synthase) activity (Dumonceaux & Carlsen
2001).
In order to elucidate the mechanism of metastasis in this cell model system, it is important
to identify genes that are differentially expressed in highly metastatic versus poorly metastatic
cell lines. Subtractive hybridization is a powerful approach to isolate differentially expressed
genes (Wang & Brown 1991; Wan & Erlander 1997; Vedoy et al. 1999). Therefore, here, we have
used this method along with differential screening to identify genes that were differentially
expressed in highly metastatic (LN4.D6) and poorly metastatic (CAb.D5) cell lines. We found
that eight forward cDNA clones in CAb.D5 and six reverse cDNA clones in LN4.D6 cell lines
were differentially expressed compared with each other. However, no correlation was found
between the expression patterns of the differentially expressed genes and metastasis in highly
metastatic LN4.D6 compared with MAT.LyLu cell line and poorly metastatic CAb.D5 and the
non-metastatic AT1 cell line.
MATERIALS AND METHODS
Cells and culture conditions
LN4.D6 and CAb.D5 were both clones derived from the highly metastatic LN4 and poorly
metastaic CAb R3230AC cell lines, respectively (Buckly & Carlsen 1988; Carlsen et al. 1990;
Carlsen et al. 1993). Highly metastatic MAT-LyLu and non-metastatic AT1 rat prostate
adenocarcinoma cell lines were obtained from European Collection of Cell Cultures (ECACC).
All cell lines, including a normal rat fibroblast cell line, Rat.2 from ECACC were maintained in
RPMI 1640 medium supplemented with 10% calf serum, penicillin (100 U/ml) and streptomy-
cin sulphate (100 mg/ml). The same medium contained 200 mm glutamine and 100 mm dexam-
ethasone in order to improve the plating efficiency of MAT.LyLu and AT1 cell lines. Cells were
incubated at 37 °C in 5% CO2, 95% air in a humidified incubator. When they reached 60–80%
confluence, they were collected for RNA isolation.
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RNA isolation
Total RNA was isolated from 60 to 80% confluent cells according to the method of Chomczynski
& Sacchi (1987). Messenger RNA (mRNA) was isolated from total RNA using oligo (dT) cellulose
or NucleoTrap mRNA Purification Kits (Clontech, Palo Alto, CA, USA). Isolated RNA pellets
were resuspended in water, quantified by spectrophotometry and stored at −70 °C.
Subtractive hybridization
PCR-Select cDNA subtraction was carried out as described in the Clontech subtractive hybrid-
ization kit protocol. Briefly, mRNA (2 µg) from Cab.D5 or LN4.D6 was reverse transcribed to
cDNA with cDNA synthesis primer in the presence of 20 units of AMV reverse transcriptase and
dNTPs at 42 °C for 1.5 h in an air incubator. After performing second-strand cDNA synthesis
at 16 °C for 2 h, double-stranded (ds) cDNA of either Cab.D5 (tester) or LN4.D6 (driver) was
cut with RsaI restriction enzyme. Two different adaptors (adaptor 1 or adaptor 2R) were ligated
to the RsaI-digested tester cDNA. After analysis of ligation efficiency, Cab.D5 tester cDNA with
adaptor 1 or adaptor 2R was mixed with LN4.D6 driver cDNA for first hybridization at 68 °C
for 8 h to obtain forward-subtracted cDNA. In order to further enrich for differentially expressed
sequences, a second hybridization was carried out overnight at 68 °C. New hybrid molecules
with different adaptors on each end were amplified with 50 × Advantage cDNA Polymerase mix
(Clontech) in a Perkin Elmer GeneAmp PCR System 2000 thermocycler (27 cycles: 94 °C, 10 s;
66 °C, 30 s; 72 °C, 1.5 min). The same protocol was applied to generate reverse-subtracted
cDNA where LN4.D6 served as tester and CAb.D5 was the driver.
Subtracted cDNA library construction and differential screening
PCR products of subtracted cDNA were further amplified using nested primers for adaptor 1 and
adaptor 2R with Taq Polymerase (Qiagen, Hilden, Germany) at 18 cycles: 94 °C, 10 s; 68 °C,
30 s; 72 °C, 1.5 min. These secondary PCR products were ligated to pCR2.1 plasmid vector (T/
A cloning kit, Invitrogen, San Diego, CA, USA) according to the manufacturer’s directions.
INV F′ competent cells were transformed with pCR2.1 constructs and transformants selected
based on colour formation on Luria broth plates containing ampicillin and X-gal (Sigma, St
Louis, MO, USA).
Randomly picked white transformant colonies were grown in a 96-well plate for differential
screening. One microlitre of each bacterial culture was transfered to a 96-well plate and amplified
with nested primers at 23 cycles; 95 °C, 30 s; 68 °C, 3 min in Perkin Elmer GeneAmp PCR
System 9600 (Perkin Elmer, Norwalk, CT, USA). After verification of each PCR product on a
1.5% agarose ethidium bromide gel, two identical dot blots of PCR products were prepared to
hybridize with either forward- or reverse-subtracted cDNA probes. For dot blots, 5 µl of each
PCR product was combined with 0.6 N NaOH, and 3 µl of this mixture was then transferred to
nylon membrane and cross-linked with UV Stratalinker (Stratagene, La Jolla, CA, USA).
Preparation of cDNA probes and dot blot hybridization
Adaptor sequences of secondary PCR products of forward- or reverse-subtracted cDNA were
removed using RsaI, EagI and SmaI restriction enzymes. PCR products were purified with
Qiaquick PCR purification kit (Qiagen) and labelled with [α-32P]dCTP using random priming
as described in PCR-Select Differential Screening kit (Clontech).
Each dot blot was hybridized either with forward- or reverse-subtracted cDNA probe according to
the manufacturer’s directions (Clontech). Membranes were pre-hybridized in ExpressHyb solution
at 72 °C for 60 min and hybridized with [α-32P]dCTP-labelled cDNA probe overnight at 72 °C.
Membranes were then washed and exposed to X-Omat AR film (Kodak) at 70 °C for up to 2 days.
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Northern blot analysis
Messenger RNA (2.5 µg per lane) was electrophoresed on a 1.2% agarose-formaldehyde gel and
then transfered to nylon membrane (Boehringer Mannheim, Mannheim, Germany) by capillary
action. Blots were pre-hybridized with ExpressHyb solution (Clonetech) for 1 h, hybridized with
probes and labelled with [α-32P]dCTP by random priming for 2 h at 68 °C. Membranes were
washed three times with 2 × SSC, 0.2% sodium dodecyl sulfate (SDS) at room temperature
for 10 min each, followed by two washes with 2 × SSC, 0.2% SDS at 50 °C for 20 min each.
Membranes were exposed to X-Omat AR film (Kodak) or a Molecular Imager screen (Bio-Rad
Laboratories, Hercules, CA, USA) for up to 24 h. The sizes of mRNA transcripts were deter-
mined by comparison with RNA Marker I (Promega, Madison, WI, USA).
cDNA sequencing
Individual bacterial colonies containing pCR2.1 plasmid vector with differentially expressed cDNA
fragments were grown overnight in 2 ml Luria broth supplemented with 100 µg/ml ampicillin
(Sigma). Plasmid DNA was isolated by a rapid alkaline lysis method and electrophoresed on a
1% agarose gel. Plasmids containing cDNA inserts were sequenced with an automated
sequencer (310 Genetic Analyser, ABI Prism). DNA sequences were analysed for homologies
to known DNA/mRNA sequences through blast search of GeneBank Database at the National
Center for Biotechnology Information (National Institute of Health, Bethesda, MD, USA).
RESULTS
Subtractive hybridization
Subtractive hybridization was used in order to determine differentially expressed genes in the
highly metastatic LN4.D6 and poorly metastatic CAb.D5 cells. An outline of this approach is
shown in Fig. 1. Subtractive hybridization consists of generating double-stranded (ds) cDNA
from mRNA of two cell lines which serve as either tester or driver, digesting of tester or driver
cDNA with RsaI enzyme to get blunt-ended cDNA, creating two tester populations with different
adaptors, and first and second hybridization of tester and driver cDNA to generate differentially
expressed sequences. In order to exponentially amplify only differentially expressed sequences,
subtracted cDNA was amplified using suppression PCR (Siebert et al. 1995) in which a pan-like
structure occurs when complementary sequences are present on each end of the single-stranded
DNA. During the secondary PCR amplification, the background was reduced and differentially
expressed sequences further enriched using nested primers. In this experiment, we generated
forward-(CAb.D5 tester; LN4.D6 driver) and reverse-subtracted cDNA (LN4.D6 tester;
CAb.D5 driver). Subtraction efficiency was confirmed by reduction of a housekeeping gene
G3PDH abundance in forward- or reverse-subtracted cDNA but not in unsubtracted cDNA (data
not shown).
Differential screening of forward- and reverse-subtracted clones
When membranes prepared from forward-subtracted cDNA (Fig. 2a and b) were compared with
each other, many strong hybridizing dots appeared on the membrane probed with forward-
subtracted cDNA (Fig. 2a); however, only one dot was apparent on the membrane probed with
reverse-subtracted cDNA (Fig. 2b) indicating that differentially expressed genes in CAb.D5 cells
were successfully subtracted. Similarly, comparison of the membranes prepared from reverse-
subtracted cDNA (Fig. 2c and d) showed that the membrane probed with reverse-subtracted
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cDNA (Fig. 2c) had many more strongly hybridizing dots than the membrane probed with
forward-subtracted cDNA (Fig. 2d).
Twenty-eight clones from forward-subtracted cDNA and 18 clones from reverse-subtracted
cDNA were further tested with northern blot analysis for the confirmation of differentially
expressed genes in LN4.D6 and CAb.D5 cells lines.
Northern blot and identification of sequences for differentially expressed genes
In order to confirm differential gene expression between LN4.D6 and CAb.D5 cells selected by
differential screening, northern blot analysis had been carried out and sizes of mRNA transcripts
detected by the cDNA clones were determined.
A total of 28 randomly selected forward-subtracted cDNA clones were screened with northern
blotting and 18 of the clones were positive for differential gene expression in CAb.D5 cells;
however, 40% of the screened clones were false positive. All positive clones [FA-8, FB-5 (absent
in figure), FC-6, FC-7, FF-10, FC-1, FH-2 and FG-6] were observed to be expressed only in
CAb.D5 (Fig. 3a) but not in the LN4.D6 cell line.
In addition, using northern blot analysis, 11 of 18 reverse-subtracted cDNA clones were
confirmed to be positive for differential gene expression in the LN4.D6 cell line (Fig. 3b). The
clones RB-8, RB-9, RE-1, RE-12 and RF-5 were expressed only in the LN4.D6 cell line. In
contrast, the RD-4 clone was expressed in both cell lines (only Fig. 3b has it) but the expression
level of RD-4 was twofold higher in LN4.D6 than in CAb.D5.
In order to determine if any of the isolated clones were identical or if they corresponded to
previously characterized genes, sequencing of the cDNA clones was carried out. Sequence data
Figure 1. Schematic representation of the procedure for isolation of differentially expressed genes in CAb.D5 and
LN4.D6.
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of each clone was compared with known sequences using the blast homology search program.
With this approach, we were able to identify six cDNA clones, FA-8, FC-1, FC-6, FC-7, FF-10,
FH-2 which showed homologies to previously sequenced genes, corresponding to, respectively,
alpha 2 collagen IV, aldehyde dehydrogenase, pro-alpha 1 collagen III, ribosomal protein
L4, osteoblast /osteocyte factor 45, and cytokeratin 8. The remaining one cDNA clone FG-6
presented no homologies with known sequences (Table 1).
The same analysis was carried out for differentially expressed cDNA clones in the LN4.D6
cell line and five cDNA clones were identified as having homologies to known genes (Table 1).
However, the cDNA RE-12 had no sequence match in the blast. Full-length cDNA-sequence
analysis of the novel genes is under investigation.
Expression profile of differentially expressed genes in different cell lines
Northern blot analysis was performed to determine whether there was a correlation between the
expression profile of differentially expressed genes and metastasis in two pairs of rat adeno-
carcinoma cell lines with low and high metastatic potential. Even though forward-subtracted genes
were differentially expressed in CAb.D5 cells compared with LN4.D6 cells, the expression
pattern of these genes in CAb.D5 and LN4.D6 did not show any similarity to that of the genes
of the rat prostate MAT-LyLu and AT1 cells (Fig. 4, Table 2). However, only the expression
Figure 2. Differential screening of subtracted cDNAs. Randomly chosen bacterial colonies from forward- or reverse-
subtracted cDNA library were grown in 96-well plate, amplified with PCR and arrayed on nylon membranes. (a) and
(b) are identical membranes for forward-subtracted clones; (c) and (d) for reverse-subtracted clones. The membranes
(a) and (d) were hybridized with a forward-subtracted cDNA probe; the membranes (b) and (c) hybridized with a
reverse-subtracted cDNA probe. Wells number A-1 and A-4 of membrane (a) served as negative controls for hybridiza-
tion (testis specific protein cDNA).
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Figure 3. Northern blot analysis of forward- and reverse-subtracted cDNA clones. Each membrane containing
mRNA for CAb.D5 and LN4.D6 cell lines was probed with a different cDNA clone. Membranes in (a) were probed with
forward-subtracted cDNAs, membranes in (b) were probed with reverse-subtracted cDNAs. For the confirmation of
mRNA in both lanes, the membranes were stripped and labelled with G3PDH internal control.
© 2003 Blackwell Publishing Ltd, Cell Proliferation, 36, 333–346.
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profile of FA-8 had some similarity in the two pairs of cell lines, in that FA-8 gene expression
was high in poorly metastatic CAb.D5 and non-metastatic AT1 cell lines compared with highly
metastatic LN4.D6 and MAT-LyLu cell lines (Table 2). In addition, FF-10 gene expression was
observed only in CAb.D5 cells (Fig. 4). Except FF-10, all forward-subtracted cDNA clones were
expressed in Rat.2 cell line (Table 2). Moreover, the expression level of FG-6 was the highest
in Rat.2 cell line compared with the other cell lines.
Table 1. Differentially expressed cDNA clones in higly metastatic LN4.D6 and poorly metastatic CAb.D5 cell lines
 
 
Table 2. Relative expression levels of mRNA for differentially expressed genes in different cell lines
 
 
Clone Number of sequenced 
nucleotides
Size of mRNA 
(kb)
Sequence % homology Number of 
clones
FA-8 236 2.7 Rat alpha 2 collagen IV 87 1
FB-5 – 2 ND 1
FC-1 360 1.6 Rat aldehyde dehydrogenase 99 1
FC-6 226 4.6 Rat proalpha 1 collagen III 92 1
FC-7 218 0.8 Ribosomal protein L4 93 1
FF-10 463 1.3 Osteoblast/osteocyte Factor 45 95 1
FG-6 282 0.5 Novel 3
FH-2 297 1.8 Rat cytokeratin 8 95 9
RB-8 536 1 Neutrophil chemoattractant 2 95 2
RB-9 410 1.6 Human LGN protein 85 1
RD-4 88 1.3 Mouse aspartylaminopeptidase 89 1
RE-1 417 1.6 Rat keratin (C K5) mRNA 97 3
RE-12 361 1 Novel 1
RF-5 321 1.4 Mouse keratin (epidermal) type 1 95 3
cDNA clones were obtained by subtractive hybridization of CAb.D5 and LN4.D6 cells. Forward- and reverse-subtracted 
clones are designated as FA-8 to FH-2; and RB-8 to RF-5, respectively. ND, not determined.
Clones Cell lines 
LN4.D6 CAb.D5 MAT-LyLu AT1 Rat.2
FA-8 – 242 140 210 60
FB-5 ND ND ND ND ND
FC-1 – 121 157 147 140
FC-6 – 232 93 52 24
FC-7 110 233 168 183 190
FF-10 – 120 – – –
FG-6 80 190 150 166 320
FH-2 – 215 166 113 47
RE-1 150 – – – –
RB-9 206 113 140 180 280
RF-5 252 – – – –
RD-4 145 95 145 190 460
RB-8 235 – – – –
RE-12 130 60 30 70 80
Expression levels of differentially expressed forward- and reverse-subtracted genes was determined by northern blot 
analysis. Level of mRNA was quantified with phosphor imager and normalized with the level of G3PDH. Identity of 
forward- and reverse-subtracted clones are indicated in Table 1.
ND, not determined.
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Figure 4. Expression profile of differentially expressed genes in different cell lines. Northern blot membranes of
FA-8, FC-6, FC-1, FH-2, FF-10 and RB-8 were stripped and labelled with G3PDH as an internal control.
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Similarly, the expression pattern of differentially expressed reverse-subtracted genes in
LN4.D6 and CAb.D5 did not correlate with that of the genes in MAT-LyLu and AT1 cell lines
(Table 2). In addition, RB-8 (Fig. 4), RE-1, and RF-5 were exclusively expressed in LN4.D6
(Table 2). Finally, the expression level of RD-4 clone was almost threefold higher in Rat.2 cell
line compared with other cell lines (Table 2).
DISCUSSION
Cancer metastasis is regulated by the activation and inactivation of many genes in different
cancer types (Ahmad & Hard 1997; Yokota 2000). It is possible that each step of metastasis is
controlled by transient and/or permanent changes at the mRNA level of different genes. There-
fore, in the present study, we investigated differentially expressed genes in highly metastatic
(LN4.D6) and poorly metastatic (CAb.D5) subpopulations of R3230AC rat mammary adeno-
carcinoma cells using a subtractive hybridization technique which enables efficient and rapid
cloning of even rarely transcribed differentially expressed genes. We found that eight cDNA
clones in CAb.D5 and six cDNA clones in LN4.D6 cells were differentially expressed (Table 1).
Invasion of the extracellular matrix by tumour cells is an important step in the metastatic
cascade (Ahmad & Hart 1997). Extracellular matrix is composed of basement membrane and
interstitial connective tissue and type IV collagen is one of the important components of base-
ment membrane. Collagen fibres such as those of types I, II, and III are main components of
interstitial connective tissue. The enzymes produced by cancer cells, stromal cells and host
leucocytes can degrade the extracellular matrix (Liotta et al. 1983). Because collagens are
important components of the extracellular matrix which functions as a barrier for tumour cell
invasion, the decrease in expression levels of collagens may facilitate cells to become metastatic.
In addition, Martinelle-Catusse et al. (2001) demonstrated that alpha 3 collagen IV inhibits the
invasive properties of an epithelial bronchial cell line, BZR. Moreover, a high level of type IV
collagen expression and lower cell proliferation rate was observed in benign tumours compared
with T4 thyroid carcinoma (Kusunoki et al. 2002). Therefore, in our study, expression of alpha 2
collagen IV and pro-alpha 1 collagen III in poorly metastatic CAb.D5 cells, but not in the highly
metastatic LN4.D6, may be one of the important factors for CAb.D5 cells being less able to
metastasize than LN4.D6 cells.
The clone FC-7, that corresponds to ribosomal protein L4, was differentially expressed in CAb.D5
cells. Previous studies have shown that expression levels of protein synthesis regulators change
with metastasis. For example, the expression of ribosomal protein P2 increased in liver metastasis
when compared with primary colon carcinoma and normal colonic mucosae (Elvin et al. 1988).
However, the relative abundance of ribosomal phosphoprotein 2 was significantly higher in human
breast fibroadenomas than in highly metastatic human adenocarcinomas (Sharp et al. 1990). In
addition, Adams et al. (1992) reported that two genes encoding translation associated proteins,
elongation factor 1-α and ubiquitin carboxyl-extension, were expressed at higher level in
fibroadenomas than in carcinomas. Moreover, Daigneault et al. (1995) found that ribosomal
protein L38, ribosomal protein S4, and acidic ribosomal phosphoprotein P1 were differentially
expressed in non-metastatic SMF-Da rat rhabdomyosarcoma compared with metastatic SMF-
Ai cell line. In our study, the differential expression of ribosomal protein L4 in poorly metastatic
CAb.D5 cells, but not in highly metastatic LN4.D6, is consistent with the results of these groups.
Taken together, these studies indicate that translation-associated genes were expressed at higher
levels in non- or low-metastatic cell lines than in highly malignant or metastatic cells.
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Cytokeratins are members of the intermediate filament multigene family and are classified
in two major groups: type I (acidic cytokeratins: CK9-CK20) and type II cytokeratins (neutral
or basic: CK1-CK8). The type and specificity of cytokeratins show significant differences of
distribution among epithelial tissues and the expression pattern of cytokeratins varies with the
cell state such as proliferation, differentiation, transformation and development (Sun et al. 1984;
Simonishi et al. 2000). In addition, cytokeratins may be used as biomarkers for discriminating
primary from metastatic carcinoma (Tot 2002). In this present study, we found that cytokeratin 8
(CK8) was expressed in CAb.D5, but not in the highly metastatic LN4.D6 cells. Similar to our
finding, Zoli et al. (1997) reported that CK8 was poorly expressed, or not expressed at all, in
two new cell lines derived from metastatic human breast carcinoma. In addition, Hansson et al.
(2001) examined cytokeratin expression in normal, immortalized and malignant organotypic
epithelial cells. They found that, although CK8 expression was relatively high (30–70%) in
immortalized cells, no CK8 expression was detected in malignant epithelia.
Possible correlation between CK8 expression and inhibition of extracellular signal-related
kinase (ERK) was shown in the metastatic human breast cancer cell line MDA-MB 231
(Seddighzadeh et al. 2000). Because there are biochemical and genetic implications concerning
aberrant signalling in the ERK/mitogen-activated protein (MAP) kinase pathway contributing
significantly to the transformed phenotype (Seddighzadeh et al. 2000), CK8 expression and
ERK inhibition may be the most significant mechanisms for low metastatic potential of CAb.D5
cells in our study. Induction of CK8 expression by an ERK inhibitor in LN4.D6 cells and testing
of metastatic ability will test this hypothesis.
Bocker et al. (2002) distinguished types of breast cancer by their cytokeratin expression
patterns. Two differentiated cell phenotypes, glandular (CK5−/CK8/CK18/CK19 positive) and
myoepithelial [smooth muscle actin (SMA)] exist within human mammary gland epithelium.
More than 95% of breast cancer cases were of the pure glandular phenotype. However, carcinomas
that are CK5+/CK8/CK18/CK19-negative and SMA-negative, and malignancies of myoepithelial
type are exceptionally rare. Based on their study, it is probable that the CAb.D5 cell line would
have a glandular phenotype and LN4.D6 would have a myoepithelial phenotype (CAb.D5
expresses CK8; LN4.D6 expresses CK5). In addition, differential expression of CK8 in CAb.D5
cells may be responsible for the low metastatic potential of this cell line. Future transfection
studies of the CK8 gene into LN4.D6 or human metastatic cell lines will elucidate whether CK8
has a different effect on tumour metastasis in different species. Furthermore, Al-Hajj et al.
(2003) distinguished tumourigenic from non-tumourigenic breast cancer cells based on expres-
sion of cell-surface differentiation markers. Identification of cell-surface differentiation antigens
as well as stem-cell differentiation markers (Bocker et al. 2002) will provide additional
information for phenotypic characterization of CAb.D5 and LN4.D6 cells in order to explain
their metastatic potential.
Unlike the studies described here, expression of CK8 and tumour progression have been
reported by other workers within benign and malignant breast tissue (Brotherick et al. 1998),
medullary carcinoma of breast (Tot 2000), non-small cell lung cancer cell lines (Fujita et al.
1999 and Fukunaga et al. 2002) and colorectal cancer cells (Sasaki et al. 1998). In addition,
Hembrough et al. (1997) has shown that CK8 promoted plasminogen activation which is
involved in cellular migration and tumour invasion. Results from these studies indicate that
type of cytokeratin expression changes from tissue to tissue and alteration in the expression
of individual cytokeratins requires further investigation to determine any correlation with
metastasis.
A further differentially expressed gene (FC-1), in forward-subtracted clones was aldehyde
dehydrogenase. Expression of this gene was undetectable in LN4.D6 cells, however, it was
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expressed at similar levels in CAb.D5, Mat.LyLu, AT1 and Rat.2 cell lines (Table 2). The
metastatic relevance of this gene in rat mammary adenocarcinoma needs further investigation.
The clone FF-10 showed a significant homology (95%) with osteoblast /osteocyte factor 45
(OF45). Petersen et al. 2000 identified OF45 as a novel bone-specific cDNA in a rat bone
marrow-derived osteoblasts using subtractive hybridization. These workers detected a single
2-kb mRNA transcript in bone and expression of its gene was not detected in other tissues. In
contrast, the molecular weight of the FF-10 transcript was 1.3 kb in our work. Similar to their
results, multitissue northern blot (Clontech) analysis showed that FF-10 was not expressed in
other rat tissues, such as heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis in
this study (data not shown). Specific expression of FF-10 transcript only in CAb.D5 cells, but
not in other cells (Fig. 4), could indicate a possible function of this gene in low metastatic poten-
tial of CAb.D5 cells.
In reverse subtraction, five differentially expressed clones (RB-8, RB-9, RD-4, RE-1, RF-5)
showed homology with known sequences (Table 1). A novel human mosaic protein LGN was
first cloned and identified as protein that interacts with α-subunit of the heterodimeric GTP-
binding protein, Gi2 (Mochizuki et al. 1996). Full-length cDNA was obtained from the HeLa cell
cDNA library and the appropriate protein contains 10 Leu-Gly-Asn repeats (LGN). mRNA of
LGN was present in all human tissues. Similar to their results, LGN (RB-9 clone) was expressed
in every cell examined in this present study. The expression level was 1.8-fold higher in LN4.D6
than it was in CAb.D5 (Table 2) and, as LGN interacts with GTP binding protein which mediates
transmembrane signalling for receptors, it will be of specific interest for further investigation of
metastatic relevance.
The clones RE-1 (CK5) and RF-5 (mouse epidermal type 1 cytokeratin) were expressed at
the same frequency in LN4.D6 cells (Table 1), whereas no expression was detected in the
CAb.D5 cell line. Similar to our result, Hansson et al. (2001) reported that CK5 expression was
highest (30–70%) in malignant organotypic oral epithelia when compared with immortalized
epithelia (less than 5%). Pencil et al. (1993) showed that CK7 expression was twofold higher in
highly metastatic versus low metastatic cell line of rat 13762NF mammary adenocarcinoma cells.
In addition, mouse epidermal cytokeratin (intermediate filament subunit II) was differentially
expressed in placental tissue which invades the maternal uterus and shares features with invasion in
malignancy (Kataoka et al. 2001). Again, these studies show possible involvement of cytokeratins
in metastasis, but the type and function of a specific cytokeratin changes between tumour types.
blast search for partial cDNA sequences of clones FG-6 in forward subtraction and RE-12
in reverse subtraction showed no homology with known genes. Full-length cDNA sequence and
metastatic relevance of these novel genes in other cell lines will be identified in further studies.
Finally, we examined the expression pattern of differentially expressed genes in two pairs of
cancer cell lines: rat mammary adenocarcinoma (LN4.D6, CAb.D5) and rat prostate adenocar-
cinoma (MAT.LyLu and AT1). We found that the expression levels of all differentially expressed
genes did not correlate with the metastatic potential of the cells. However, the expression level
of FA-8 (alpha 2 collagen IV) showed a slight correlation with metastatic potential in which FA-
8 was expressed in CAb.D5 only, but not in LN4.D6, and the expression level of FA-8 was found
to be 1.5-fold higher in non-metastatic AT1 than in highly metastatic MAT.LyLu. Although there
is no direct evidence from the literature concerning involvement of these differentially expressed
genes in the metastatic process, it is likely that products of these genes may be directly or indi-
rectly involved in metastasis, rather than simply being up-regulated as a result of altered cell
phenotype. Further investigation of the expression profile of differentially expressed genes in a
larger series of metastatic and non-metastatic mammary adenocarcinoma cell lines may explain
this possibility.
© 2003 Blackwell Publishing Ltd, Cell Proliferation, 36, 333–346.
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In addition, in comparison with other cell lines, FF-10 was expressed only in CAb.D5,
whereas RB-8, RE-1 and RF-5 were expressed only in LN4.D6 cells. Therefore, cell-specific
expression of these differentially expressed genes will be the first target for future experiments
related to metastatic potential of the cells.
In conclusion, we performed subtractive hybridization to differentiate genes expressed in
highly metastatic LN4.D6 and poorly metastatic CAb.D5 cell lines. Eight cDNA clones in
CAb.D5 and six cDNA clones in LN4.D6 were found to be differentially expressed. One cDNA
clone in each cell line (FG-6 in CAb.D5; RE-12 in LN4.D6) has been shown to be novel. Iden-
tification of full-length cDNA sequences of these clones is under investigation. The expression
profiles of differentially expressed genes in two pairs of rat adenocarcinoma cell lines did not
show any correlation between expression of these genes and metastatic potential of the cell lines.
However, it will be necessary to look at the expression pattern of these genes in a series of
metastatic and non-metastatic cell lines from various mammary adenocarcinomas. Subsequently,
further studies involving transfection of cDNA constructs of differentially expressed genes will
help to elucidate the role of the genes in the metastatic process.
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